After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for chronic lymphocytic leukemia.

CHICAGO — Asciminib demonstrated superior efficacy to standard first-line therapies for certain patients with newly diagnosed chronic myeloid leukemia, according to study results presented at ASCO ...

AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic ...

Chronic myelomonocytic leukemia (CMML) is a rare type of blood cancer. Some people live a long time with CMML, but others go on to develop acute myeloid leukemia (AML). Chronic myelomonocytic leukemia ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells grow.

—The gene mutations that drive progression in CML are unclear. A new study found that mutations in activated signaling and myeloid transcription factor genes at diagnosis were associated with worse ...

The choice of frontline therapy for a patient with chronic phase chronic myeloid leukemia (CP-CML) can have a profound effect on the long-term clinical outcome. Currently, five tyrosine kinase ...

Domain adaptation may be a novel creative solution to predict infection risk in patients with chronic lymphocytic leukemia ...

"I know physicians are busy, but I’m treating a patient, not a disease. I take a holistic approach. I think we need to make physicians who treat chronic myeloid leukemia treat the disease and make ...

Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.